Here at the Genitourinary Cancer Symposium in Orlando, Florida we’ve been hearing intriguing news about potentially management-changing practices in bladder, renal and, of course, prostate cancer.

Comprehensive genomic profile could be a way of unlocking a treasure trove of targets in metastatic bladder cancer. That’s according to Dr Jeffrey Ross who has been looking at genomic alterations that make it possible to use known drugs to target this disease.

In hormone naïve patients with metastatic prostate cancer, early use of docetaxel might not be as useful, that’s according to Dr Gravis. She’s reported that the volume of the disease is an important issue.

There was a big difference among patients with high risk localised prostate cancer reported here in Orlando at the Genitourinary Cancers Symposium. Dr Scott Tyldesley reported that brachytherapy was better than external beam radiotherapy.

Dual mTOR inhibition was not superior to standard mTOR inhibition for treating metastatic clear cell renal carcinoma. Professor Tom Powles found that a new compound that inhibits both TORC1 and TORC2 was not any better.

Extended disease control, up to five years and more, in synchronous metastatic renal cell cancer was reported by Robert Figlin using sunitinib combined with a vaccine.

When, or indeed whether, to use castration for localised prostate cancer was researched by Frederik Thomsen who found that there is still a good case to be made out for watchful waiting.